PT  - JOURNAL ARTICLE
AU  - Juan C. Muñoz-Sánchez
AU  - Santiago F. Elena
AU  - José–Angel Oteo
TI  - Application of Carleman approximants for the estimation of epidemic parameters from incidence data time-series
AID  - 10.1101/2022.07.14.22277622
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.14.22277622
4099  - http://medrxiv.org/content/early/2022/07/15/2022.07.14.22277622.short
4100  - http://medrxiv.org/content/early/2022/07/15/2022.07.14.22277622.full
AB  - We have analyzed the possibility of estimating epidemiological parameters from daily infection incidence data. In particular, we have focused on the determination of the instantaneous reproduction number, the contagion period and the duration of the infectious period using only the reported incidence time-series information. We have developed a data-driven method based on the instantaneous mapping of the infection incidence data on the simplest (two parameter) SIR model, along the progression of an epidemy. The mapping is carried out via Carleman linearization of the non-linear model equations. We concluded that the daily infection incidence series on its own does not carry enough information to provide estimates for the above time scales and hence additional measurements and/or hypotheses must be considered. In contrast, the prevalence time-series does allow for accurate estimates. For the case in which the characteristic infectious period is available, a new algebraic formula for the instantaneous reproduction number has been derived.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJCMS was supported by Generalitat Valenciana Plan GenT grant ACIF/2021/296. SFE was supported by European Commission - NextGenerationEU (Regulation EU 2020/2094) through CSIC Global Health Platform (PTI Salud Global) grants SGL2021-03-009 and SGL2021-03-052. JAO work was partially supported by the Spanish Agencia Estatal de Investigación (grant number PID2019-109592GB-100).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used (or will use) ONLY openly available human data that were originally located at: https://dadesobertes.gva.es/va/dataset/covid-19-series-casos-pdia-positiva https://coronadatos.es/Gr%C3%A1ficas/NumeroReproductivo/C-Valenciana/2020-03-13/2021-12-01/l%C3%ADneasI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript